Business Context and Reporting Period
This Form 8-K filing by Athira Pharma, Inc. (trading symbol: ATHA) reports on the results of the 2022 Annual Meeting of Stockholders held on May 19, 2022. The filing details the voting outcomes for director elections, auditor ratification, and a stockholder proposal regarding bylaw amendments. Note: The request metadata references "Leonabio, Inc.," but the source text explicitly identifies the registrant as Athira Pharma, Inc.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing reports the following material outcomes from the Annual Meeting:
- Shareholder Participation: 32,995,908 shares (approximately 87.7% of entitled shares) were present in person or by proxy.
- Proposal 1 (Election of Class II Directors):
- The three nominees proposed by the Board of Directors (Joseph Edelman, John M. Fluke, Jr., and Grant Pickering) were elected.
- Two nominees proposed by stockholder Richard A. Kayne (Richard A. Kayne and George W. Bickerstaff, III) were not elected.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Proposal 3 (Bylaw Amendments): A stockholder proposal submitted by Mr. Kayne to repeal certain bylaw provisions was not approved.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the context of the contested director election and the failed stockholder proposal. The text notes that the definitive proxy statement filed on April 5, 2022, contains more detailed descriptions of the proposals.
Key Facts for Investor Verification
- Verify the current board composition following the election of the three Board nominees and the rejection of the two dissident nominees.
- Confirm the status of the company's bylaws, as the proposal to repeal specific provisions was defeated.
- Review the April 5, 2022, proxy statement for detailed context on the governance disputes and the specific bylaw provisions in question.
- Note that this document contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.